2026 Oncology Billing and Coding Changes: What Oncology Practices Need to Know

Oncology Revenue Cycles Are Becoming Increasingly Complex

The 2026 oncology reimbursement environment represents one of the most operationally challenging periods oncology practices have faced in years. While oncology has always carried substantial billing and coding complexity because of high-cost drugs, infusion services, radiation treatment workflows, and Medicare-heavy reimbursement structures, the 2026 changes introduce additional operational pressure involving radiation oncology coding transitions, image-guidance bundling, ASP drug-payment monitoring, prior authorization requirements, NCCI bundling rules, and reimbursement methodology changes.

For oncology practices, the greatest financial risk is no longer simply coding incorrectly. Increasingly, the larger risk involves silent operational revenue leakage occurring across payer implementation delays, bundled-service confusion, modifier errors, underpayments, authorization gaps, and documentation deficiencies.

The most significant oncology-specific disruption in 2026 is occurring in radiation oncology.

Radiation Oncology: The Biggest Oncology Coding Disruption in 2026

Radiation oncology underwent a major coding and reimbursement restructuring in 2026. The American Society for Radiation Oncology (ASTRO) has identified revised radiation treatment delivery codes as one of the largest operational concerns affecting oncology practices this year.

Key revised treatment delivery codes include:

• 77402
• 77407
• 77412

ASTRO continues monitoring:

• payer denials,
• downcoding,
• underpayments,
• reimbursement inconsistencies, and
• implementation delays associated with these revised treatment delivery structures.

One of the most operationally important changes involves image guidance reimbursement.

Beginning in 2026, Medicare consolidated image guidance into CPT code:

• 77387

At the same time, several prior image-guidance codes were deleted:

• G6001
• G6002
• G6017
• 77014

Additionally, the technical component of image guidance is now bundled into treatment delivery codes 77402–77412.

This bundling change creates major operational implications because many practices historically billed image guidance separately.

Practices that fail to understand the new bundling rules may experience:

• denied claims,
• duplicate billing edits,
• reimbursement reductions,
• compliance exposure,
• and increased audit risk.

Operationally, radiation oncology remains one of the most complex reimbursement environments in healthcare because it combines:

• physician billing,
• technical billing,
• treatment planning,
• dosimetry,
• imaging guidance,
• equipment utilization,
• prior authorization, and
• highly specialized Medicare reimbursement rules.

The 2026 transition significantly increases the importance of coding specificity, workflow education, payer monitoring, and denial prevention infrastructure.

Medicare Payment Methodology Changes

The 2026 Medicare Physician Fee Schedule created additional reimbursement pressure across oncology specialties.

The American Society of Clinical Oncology (ASCO) reported that CMS finalized significant physician reimbursement methodology changes affecting oncology reimbursement structures. However, after substantial ASCO advocacy efforts, drug administration codes were exempted from some of the reimbursement reductions for 2026.

This exemption is critically important because oncology practices rely heavily on:

• infusion services,
• chemotherapy administration,
• biologic administration,
• immunotherapy workflows,
• and outpatient drug-delivery revenue.

Without this exemption, many oncology groups could have faced even greater financial pressure.
However, despite temporary relief surrounding drug administration services, oncology practices continue facing broader reimbursement compression involving:

• physician payment reductions,
• operational overhead increases,
• staffing costs,
• payer scrutiny,
• and administrative burden expansion.

Oncology Drug Billing and ASP Monitoring

One of the most operationally important aspects of oncology revenue-cycle management remains Medicare Part B drug billing.

CMS continues publishing quarterly:

• ASP payment limit files,
• drug reimbursement updates,
• and NDC-HCPCS crosswalk files.

For oncology practices, these quarterly updates are extremely important because oncology reimbursement depends heavily on:

• chemotherapy drugs,
• immunotherapy agents,
• biologics,
• biosimilars,
• infused medications,
• and high-cost outpatient pharmaceuticals.

Operationally, practices must continuously monitor:

• ASP pricing changes,
• underpayments,
• NDC mapping accuracy,
• HCPCS alignment,
• reimbursement reductions,
• biosimilar payment shifts, and
• payer-specific reimbursement behavior.

Many oncology practices underestimate the degree of silent revenue leakage that may occur through:

• incorrect NDC mapping,
• outdated pricing files,
• modifier errors,
• payer underpayments, and
• reimbursement lag.

Because oncology drugs often involve extremely high-dollar claims, even small billing errors may create substantial financial exposure.

JW and JZ Modifiers: A Major Audit and Compliance Risk

JW and JZ modifiers remain one of the highest-risk operational areas in oncology billing.

For single-dose drug vials:

• JW reports discarded drug amounts
• JZ attests that no amount was discarded

These modifiers are critically important because many oncology medications involve:

• expensive biologics,
• chemotherapy agents,
• immunotherapy infusions, and
• high-cost single-dose medications.

Practices must maintain highly accurate documentation regarding:

• drug preparation,
• administration amounts,
• wastage calculations,
• discarded units, and
• billing alignment.

Operational failures involving JW and JZ modifiers may create:

• denied claims,
• underpayments,
• overpayment recoupments,
• audit exposure,
• False Claims Act risk, and
• compliance investigations.

Because oncology drug reimbursement involves extremely high financial values, CMS and commercial payers continue closely scrutinizing drug wastage reporting.

Prior Authorization Changes in Oncology

Prior authorization continues to represent one of the largest operational burdens facing oncology practices. Radiation oncology authorization policies are evolving alongside the 2026 code changes, and several payers implemented revised radiation oncology authorization requirements effective January 1, 2026.

These changes are tied directly to:

• revised CPT structures,
• HCPCS updates,
• image-guidance bundling,
• treatment-delivery revisions, and
• evolving payer utilization-management strategies.

Operationally, practices increasingly face:

• authorization delays,
• code mismatches,
• payer-policy inconsistencies,
• repeated documentation requests,
• treatment delays, and
• increased administrative staffing burden.

Because oncology treatment is highly time-sensitive, authorization failures may directly affect:

• patient care,
• scheduling,
• cash flow, and
• revenue predictability.

Practices that fail to update authorization workflows around the 2026 coding changes may experience significant denial increases.

NCCI Bundling and Coding Specificity

CMS’ 2026 National Correct Coding Initiative (NCCI) policy manual reinforces a critically important reimbursement principle:
Providers should report the code describing the service with the greatest specificity and should not separately report multiple services when one comprehensive code already describes the work performed.

For oncology practices, this has major implications involving:

• infusion billing,
• hydration services,
• injections,
• radiation treatment delivery,
• imaging guidance,
• treatment planning, and
• bundled procedural workflows.

As oncology coding becomes increasingly consolidated and bundled, practices face growing risk surrounding:

• duplicate billing,
• modifier misuse,
• unbundling errors,
• downcoding,
• payer edits, and
• compliance audits.

The 2026 environment places increasing importance on:

• coding education,
• operational workflow alignment,
• payer-policy monitoring, and
• denial analytics.

The Bigger Operational Reality

The 2026 oncology reimbursement landscape reflects a much larger transformation occurring throughout healthcare.

CMS and commercial payers are increasingly emphasizing:

• bundled reimbursement,
• operational efficiency,
• outpatient management,
• utilization control,
• documentation specificity,
• prior authorization oversight, and
• reimbursement accountability.

Final Perspective

For oncology practices, financial performance increasingly depends on the ability to integrate:

• coding accuracy,
• payer strategy,
• authorization management,
• drug-payment monitoring,
• denial prevention,
• workflow optimization, and
• operational infrastructure.

The greatest oncology revenue risk is no longer simply billing incorrectly.
It is the silent operational leakage occurring across:

• radiation oncology code transitions,
• image-guidance bundling,
• ASP reimbursement variability,
• JW/JZ modifier management,
• infusion documentation,
• authorization workflows, and
• payer implementation inconsistencies.

Pract-Eaze

Pract-Eaze works with private practices, healthcare organizations, and healthcare technology partners to strengthen revenue performance by aligning workflows, improving visibility, and ensuring that systems translate into measurable financial outcomes.

📞 (724) 512 5777
✉️ info@pract-eaze.com
🌐 www.pract-eaze.com

Dr. Renu Joshi, MD, EMBA, FACOG
OB-GYN | Private Practice Physician | Physician-Entrepreneur
Founder, Pract-Eaze